MarieJosé Kersten
@Kersten_MJ
Professor of hematology at Amsterdam UMC, specialized in B-cell malignancies and novel therapies
#ESHCART2025: PROGRAMME HIGHLIGHT: Keynote lecture by @MarcoRuella REGISTER NOW➡bit.ly/3TExODA 3rd How I Manage CAR-T Therapies & Bispecific Antibodies for My Patients Sept 26–28, 2025 - Stockholm Chairs: Caron Jacobson Ulrich Jäger @Kersten_MJ #ESHCONFERENCES #Lmsm
How can we make Informed Consent Forms more understandable? At #EBMT2025 in Florence, T2EVOLVE hosted a round table on reducing unnecessary complexity of Informed Consent Forms (ICFs) for patients in clinical trials. We are proud to share highlights on the T2EVOLVE website…
Groot nieuws in de strijd tegen auto-immuunziekten! 💪 @amsterdamumc en @LUMC_Leiden starten een 6-jarige klinische studie naar CAR-T-celtherapie voor patiënten met ernstige auto-immuunziekten zoals SLE, myositis en myasthenia gravis. Benieuwd? 👇amsterdamumc.org/nl/vandaag/146…
📢We’ve partnered with MD Anderson to explore recent breakthroughs in understanding the tumor ecosystem and how its various components influence cancer development, progression, diagnosis, and treatment. Learn more and save your seat! 🔗go.nature.com/44cJT9Z
👇👇👇👇👇
🚨 We’re recruiting! @fredhutch is seeking a clinician scholar in multiple myeloma — an incredible opportunity to join a world-class team, lead cutting-edge clinical research, and care for patients at a premier academic center. Outstanding environment. Unparalleled resources.…
Finally, awake after a long REMS slumber!!! @ASTCT astctjournal.org/article/S2666-…
Beautiful paper by my good friend @pkarschnia, amazing to see all your academic progress in the last decade! Highly recommended reading out in @NatRevNeurol on all things CAR-T neurotoxicity - from ICANS to TIAN and MNTs👇
New online! Neurological complications of CAR T cell therapy for cancers bit.ly/4eqkbCe
⚠#ESHCART2025: LAST CALL FOR ABSTRACT & CLINICAL CASE SUBMISSION! Proceed now➡️bit.ly/3TExODA 3rd How I Manage CAR-T Therapies & Bispecific Antibodies for My Patients Sept 26–28, 2025 Stockholm Chairs: Caron Jacobson Ulrich Jäger @Kersten_MJ #ESHCONFERENCES #Lmsm #MMsm
Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in @NatureCancer @lab_kok doi.org/10.1038/s43018…
🌍 Powerful presentation at #EHA2025 on global gender equity in hematology . 🧭 Clear message: equity gaps are real—and fixable. Where there’s a WiL, there’s a way. 💪
CONGRESS | #EHA2025 | PRESENTATION Martine Chamuleau at Amsterdam UMC presents findings on the prospective validation of end-of-treatment ctDNA-MRD by PhasED-Seq in patients with DLBCL from a national HOVON trial. N=160, median follow-up was 2.8 years. EOT ctDNA-MRD was…
#ESHCART2025 3 WEEKS LEFT FOR ABSTRACT & CLINICAL CASES SUBMISSION! Proceed now➡️bit.ly/3TExODA 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients Sept 26–28, 2025 Stockholm Chairs: Caron Jacobson Ulrich Jäger @Kersten_MJ #ESHCONFERENCES #MMsm #Lmsm
#Myeloma Paper of the Day: Consensus Panel 3 from 12th International #Waldenström macroglobulinemia Workshop recommends risk stratifying smoldering & active WM, genetic alteration screening & risk-adapted approach w/ clinical trial participation: pubmed.ncbi.nlm.nih.gov/40441983/. #mmsm
Just landed Report of Consensus Panel 3 from the 12th International Workshop on Waldenström’s Macroglobulinemia on the management of patients with high-risk disease authors.elsevier.com/a/1lAWr8THnlHEn @MayoMyeloma @Kersten_MJ @thanosdimop
Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology annalsofoncology.org/article/S0923-…
HAVE YOU CHECKED THE MAIN SCIENTIFIC TOPICS OF #ESHCART2025? Learn more ➡ bit.ly/3TExODA 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients Sept 26–28, 2025 Stockholm Chairs: Caron Jacobson, Ulrich Jäger, @Kersten_MJ #ESHCONFERENCES #MMsm #Lmsm
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment @BloodCancerJnl nature.com/articles/s4140…
A sincere thank you to the T2EVOLVE Work Group for Patients and Caregivers (WGPC)! T2EVOLVE is committed to providing patient-centered information on the innovative CAR T-cell treatment. The Work Group for Patients and Caregivers (WGPC) plays a crucial role in defining content…
Looking for patient-friendly information about CAR T-cell treatment? The T2EVOLVE Patient Hub offers valuable information about this ground-breaking treatment, available in six different languages. Gain insights through our explainer videos for patients and caregivers. 🔗…
📣 #ESHCART2025 REMINDER Abstract submission is OPEN! For more information➡️bit.ly/3TExODA 3rd How I Manage #CART Therapies & Bispecific Antibodies for My Patients Chairs: Caron Jacobson, Ulrich Jäger, @Kersten_MJ Sept. 26-28, 2025 in Stockholm, Sweden 🇸🇪 #ESHCONFERENCES